Objective
In Europe, around 80 cases of prostate cancer per 100,000 population diagnosed each year. However, very little is known about the molecular mechanisms behind this disease. A fundamental dilemma is the difficulty in identifying clinically important cancers, while they are confined to the prostate gland.
Conversely, it is important to identify clinically unimportant cancers so that patients can be spared aggressive treatment. Enhanced understanding of the molecular basis of development of this disease is sorely needed in order to enhance the treatment options and to develop more sensitive and specific prostate cancer diagnostic and prognostic tools.
MicroRNA (miRNA) are small non-coding RNA that control gene expression by effectively preventing mRNAs from being translated. The miRNAs play an important role in development and cellular processes such as differentiation, cell growth, cell death and stem cell division, all of which closely linked to cancer.
It has been shown that miRNA are aberrantly expressed in several forms of cancer e.g. leukaemia, colon, breast, and lung. Preliminary studies have indicated that the levels of certain miRNAs are altered in prostate cancer. In the proposed study archived tissue samples of prostate tumours and normal tissue will b e used to isolate miRNA that due to their short length are basically unaffected by the harsh fixation and embidding processes these samples have gone through.
Differentially displayed miRNAs will be identified using qRT-PCR and confirmed with in situ hybridisation onto tissue microarrays. The biological relevance of the miRNA is confirmed in vitro by introducing anti-miRNA probes, and predicted miRNA targets confirmed.
Further, the miRNAs potential in diagnostic use miRNA will be determined on serum samples from prostate cancer patients. This study will combine archive material with clinical data and the latest molecular technologies in order to gain novel information.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine oncology prostate cancer
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences medical biotechnology cells technologies stem cells
- natural sciences biological sciences genetics RNA
- medical and health sciences clinical medicine oncology leukemia
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2004-MOBILITY-11
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
LUND
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.